CTOs on the Move

Axon Communications

www.axon-com.com

 
At AXON, we simplify complex information to improve outcomes in healthcare, bringing together the right people with the right expertise to provide our clients with integrated, multichannel communications solutions. As an agency, we are passionate about healthcare communications and combine a personal touch with professionalism.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.axon-com.com
  • 800 Westchester Avenue Suite S-540
    Rye Brook, NY USA 10573
  • Phone: 914.701.0100

Executives

Name Title Contact Details

Similar Companies

DxTech

DxTech LLC is a Merrimack, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rockland Immunochemicals

Rockland Immunochemicals is a Gilbertsville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amer Assoc of Electrodiagnostic Medicine

Amer Assoc of Electrodiagnostic Medicine is a Rochester, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Large Scale Biology Corporation

Large Scale Biology Corporation is a Vacaville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metacrine

We are a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class therapies for patients with liver and gastrointestinal, or GI, diseases. Since our founding in 2014, we have invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities allow us to gain insights into disease targets and mechanisms and more quickly and purposefully design therapies with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed novel, proprietary farnesoid X receptor (FXR) clinical product candidates arising from a unique chemical scaffold with the potential to be best-in-class for non-alcoholic steatohepatitis, or NASH, and first- in-class for Inflammatory Bowel Disease, or IBD. In addition to our FXR program, we have continued to invest in drug discovery on other therapeutic targets that have effects on inflammation and/or fibrosis for which we believe we could develop proprietary small molecule therapies.